World's Best Scientists 2026 revealed!
Christopher Sweeney

Christopher Sweeney

D-Index & Metrics

Medicine

D-Index
93
Citations
42405
World Ranking
10708
National Ranking
5505

Overview

Christopher Sweeney is affiliated with Harvard University in the United States and has made significant contributions to the field of medicine, particularly focusing on prostate cancer research and treatment. Their work spans multiple disciplines, including biochemistry, genetics, and molecular biology.

Sweeney's research covers a range of subfields, with substantial publications in pulmonary and respiratory medicine, cancer research, oncology, radiology, nuclear medicine and imaging, and molecular biology. Their main research topics include prostate cancer treatment and research, prostate cancer diagnosis and treatment, cancer lipids and metabolism, radiopharmaceutical chemistry and applications, cancer immunotherapy and biomarkers, cancer genomics and diagnostics, and testicular diseases and treatments.

The scientist has published extensively in several prominent journals. The most frequent venues include:

  • Journal of Clinical Oncology (51 publications)
  • Annals of Oncology (18 publications)
  • European Urology (16 publications)
  • European Urology Oncology (7 publications)
  • European Journal of Cancer (6 publications)

Key recent papers by Christopher Sweeney demonstrate a focus on advanced cancer therapies and clinical trials. Some of these include:

  • "Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019" (2020, European Urology)
  • "Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study" (2021, The Lancet Oncology)
  • "Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial" (2021, The Lancet)
  • "Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial" (2022, Nature Medicine)
  • "EZH2 inhibition activates a dsRNA-STING-interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer" (2021, Nature Cancer)

Their frequent co-authors reflect an active collaboration network, including:

  • Silke Gillessen
  • Ian D. Davis
  • Anis Hamid
  • Nicholas D. James
  • Karim Fizazi

Christopher Sweeney's work integrates multiple aspects of cancer biology and treatment, with a clear focus on improving clinical understanding and therapeutic strategies for prostate and other related cancers. Their publication record and collaborative efforts indicate extensive involvement in ongoing cancer research and clinical trials within the medical community.

Best Publications

  • Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries.

    Claudia Allemani;Tomohiro Matsuda;Veronica Di Carlo;Rhea Harewood

  • Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer

    Christopher J. Sweeney;Yu Hui Chen;Michael Carducci;Glenn Liu

  • International incidence of childhood cancer, 2001-10 a population-based registry study

    Eva Steliarova-Foucher;Murielle Colombet;Lynn A G Ries;Florencia Moreno

  • Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer

    Ian D. Davis;Andrew J. Martin;Martin R. Stockler;Stephen Begbie

  • Preclinical Development and Clinical Translation of a PSMA-Targeted Docetaxel Nanoparticle with a Differentiated Pharmacological Profile

    Jeffrey Hrkach;Daniel Von Hoff;Mir Mukkaram Ali;Elizaveta Andrianova

  • Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial

    Christos E. Kyriakopoulos;Yu Hui Chen;Michael A. Carducci;Glenn Liu

  • Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017

    Silke Gillessen;Gerhardt Attard;Tomasz M Beer;Himisha Beltran

  • Redefining the Target: Chemotherapeutics as Antiangiogenics

    Kathy D. Miller;Christopher J. Sweeney;George W. Sledge

  • An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells

    Monica L. Guzman;Randall M. Rossi;Sundar Neelakantan;Xiaojie Li

  • Cabozantinib in Patients With Advanced Prostate Cancer: Results of a Phase II Randomized Discontinuation Trial

    David C. Smith;Matthew R. Smith;Christopher Sweeney;Aymen A. Elfiky

  • The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors.

    Christopher J. Sweeney;Kathy D. Miller;Sean E. Sissons;Shinichi Nozaki

  • Targeted therapy for advanced solid tumors on the basis of molecular profiles: Results from mypathway, an open-label, phase IIA multiple basket study

    John D. Hainsworth;Funda Meric-Bernstam;Charles Swanton;Herbert Hurwitz

  • Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study.

    Funda Meric-Bernstam;Herbert Hurwitz;Kanwal Pratap Singh Raghav;Robert R McWilliams

  • Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data

    Claire L. Vale;Sarah Burdett;Larysa H. M. Rydzewska;Laurence Albiges

  • Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer

    Wanling Xie;Meredith M. Regan;Marc Buyse;Susan Halabi

  • Enhancer RNAs participate in androgen receptor-driven looping that selectively enhances gene activation

    Chen-Lin Hsieh;Teng Fei;Yiwen Chen;Tiantian Li

  • Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015

    S Gillessen;A Omlin;G Attard;J S de Bono

  • Cyclooxygenase-2 expression in human pancreatic adenocarcinomas

    Michele T. Yip-Schneider;Darlene S. Barnard;Steven D. Billings;Liang Cheng

  • Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019[Formula presented]

    Silke Gillessen;Gerhardt Attard;Tomasz M. Beer;Himisha Beltran

  • The TMPRSS2:ERG Rearrangement, ERG Expression, and Prostate Cancer Outcomes: a Cohort Study and Meta-analysis

    Andreas Pettersson;Rebecca E. Graff;Scott R. Bauer;Michael J. Pitt

Frequent Co-Authors

Philip W. Kantoff
Philip W. Kantoff Memorial Sloan Kettering Cancer Center
Toni K. Choueiri
Toni K. Choueiri Harvard University
Paul L. Nguyen
Paul L. Nguyen Harvard Medical School
Quoc-Dien Trinh
Quoc-Dien Trinh Brigham and Women's Hospital
Mary-Ellen Taplin
Mary-Ellen Taplin Harvard University
Karim Fizazi
Karim Fizazi University of Paris-Saclay
Lorelei A. Mucci
Lorelei A. Mucci Harvard University
Michael A. Carducci
Michael A. Carducci Johns Hopkins University
Michael J. Morris
Michael J. Morris Memorial Sloan Kettering Cancer Center
Massimo Loda
Massimo Loda Cornell University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

While pursuing a medical degree in the USA is popular, many students explore alternative paths through online healthcare programs. These alternatives can offer greater flexibility and affordability, making them appealing to both new and returning learners.

One common concern is how much does online nursing school cost. Tuition varies widely depending on the institution, degree level, and study format, but many programs emphasize affordability to broaden access.

For those holding an RN credential, cheap rn to bsn programs offer a cost-effective path to advancing your nursing career. These bridge programs are popular among working professionals who want to qualify for specialized roles or leadership positions.

Ambitious nurses may consider earning an advanced degree through an online nursing doctorate. These programs prepare graduates for roles in research, education, and high-level administration.

If you did not major in nursing but wish to enter the field, there are now flexible options such as online direct entry msn programs for non-nursing majors. These programs enable a career switch by providing intensive, accelerated pathways into advanced nursing practice.

Best Scientists Citing Christopher Sweeney

Trending Scientists

Recently Published Articles